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Abstract 
 Whereas there is strong relationship between high blood pressure and 
increased overall and cardiovascular mortality for the general population, 
observational studies in haemodialysis patients have reported a “U” shaped 
relationship between pre-haemodialysis blood pressure recordings and patient 
survival. Previous attempts to introduce pre and post-haemodialysis blood 
pressure targets were associated with an increased the frequency of intra-
dialytic hypotension, itself an independent risk factor for mortality. On the 
other hand meta-analyses of trials of antihypertensive medications in 
haemodialysis patients, reported survival benefit for those prescribed 
medication. More recently, further meta-analyses have suggested a reduced risk 
for cardiovascular mortality benefit with r systolic blood pressures of less than 
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140 mmHg, the absolute benefit, in terms of risk reduction was greatest in 
those with the highest vascular disease burden. Even though data from current 
observational studies and studies of antihypertensive medications would suggest 
that patient survival would be greater with pre-dialysis systolic blood pressure 
should be less than 160 mmHg, there is no current data to propose specific 
blood pressure targets.  
Defining blood pressure targets can only be answered by adequately 
powered prospective randomised controlled trials comparing different targets. 
As the benefits of lowering blood pressure appear to be greatest for those with 
most vascular disease, then blood pressure targets may have to be adjusted on 
an individual risk basis, and future trials should therefore stratify patients 
according to vascular morbidity and have different targets for patients with 
differing degrees of pre-existing cardiovascular disease. 
 
 
Introduction 
 In the general population there is strong inverse relationship between 
increasing blood pressure and survival [1]. A recent meta-analysis of 34 
randomised clinical trials of blood pressure control showed that hypertensive 
patients randomised to more intense blood pressure lowering had significantly 
reduced risk of stroke [relative risk (RR) 0.71 (0.60-0.84)], coronary events 
[0.80 (0.68-0.95)], major cardiovascular events [0.75 (0.68-0.85)] and 
cardiovascular mortality [0.79 (0.63-0.97)], but not heart failure and all-cause 
death [2]. Stratification of these trials using three systolic blood pressure 
(SBP) cut offs (150, 140 and 130 mmHg) showed that a SBP/diastolic blood 
pressure (DBP) difference of -10/-5 mmHg across each cut off significantly 
reduced the risk for all outcomes. All major outcomes were reduced by lowering 
SBP a few mmHg below vs. above 130 mmHg, but the lower the starting SBP then 
the absolute risk reduction was lower, suggesting that patients with lower 
starting SBP were at a lower level for cardiovascular risk.  
 Although this meta-analysis of clinical trials would suggest tighter SBP is 
an advantage, and patients should have a target SBP of 130 mmHg, there have 
been concerns that these lower blood pressure targets are not protective and 
may actually cause harm in high risk patients, such as those with pre-existing 
cardiovascular disease, chronic kidney disease, or diabetes [3]. So whereas 
previous guidelines recommended target blood pressure levels of around 130/85 
mm Hg for patients with cerebrovascular disease, coronary heart disease, renal 
disease, and diabetes, more recent versions of these clinical guidelines now 
recommend higher target levels of 140/90 mm Hg in these higher risk patients 
[4-6]. 
 
Blood Pressure targets for patients with chronic kidney disease 
As there have been concerns that patients with greater cardiovascular 
risk should have different blood pressure targets compared to those with lower 
cardiovascular risk factors, a recent meta-analysis reported 19 trials of blood 
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pressure control in these higher risk patients, with a mean blood pressure of 
133/76 mm Hg in the intensive blood pressure control cohort compared to 
140/81 mm Hg in the less intensive treatment group, reported that those 
patients in the intensive blood pressure lowering cohort achieved relative 
reductions for major cardiovascular events (14% [95% CI 4-22]), myocardial 
infarction (13% [0-24]), stroke (22% [10-32]), albuminuria (10% [3-16]), and 
progression of retinopathy in diabetic patients (19% [0-34]) [7]. However, there 
was no significant benefit of lower blood pressures for heart failure (15% [95% 
CI -11 to 34]), cardiovascular death (9% [-11 to 26]), overall mortality (9% [-3 to 
19]), or progression to end-stage kidney disease (10% [-6 to 23]) [7]. The 
absolute benefits of these lower blood pressure targets were greatest in those 
trials which enrolled patients with vascular disease, chronic kidney disease 
(CKD), or diabetes. On the other hand patients randomised to the more intensive 
blood pressure lowering cohort were more likely to suffer severe hypotension 
(relative risk 2·68 [1·21-5·89], p=0·015), although the absolute excess was small 
(0·3% vs 0·1% per person-year), and there was no statistical difference in the 6 
trials which reported severe adverse event rates (1.2 vs 0.9% per year). 
 
Blood pressure in haemodialysis patients 
 Whereas there is a diurnal variation in blood pressure in healthy subjects, 
there are also additional changes in blood pressure profiles for haemodialysis 
(HD) patients during the cycle of the dialysis week [8], with most patients 
having a fall in blood pressure during the dialysis session, followed by a gradual 
increase in blood pressure between dialysis sessions, which may then increase 
exponentially in the few hours prior to the next session [8-11]. 
 Based on the data supporting blood pressure control in the general 
population, some clinical guideline groups issued blood pressure targets for both 
pre and post haemodialysis blood pressures [12]. However observational studies 
reported that those dialysis centres which had a greater proportion of patients 
achieving these targets also had a greater incidence of intra-dialytic 
hypotension [13]. 
 Blood pressure in any individual haemodialysis patient depends upon the 
complex interplay between sodium balance [14,15,16] and extracellular volume 
overload [17] on one hand, and vasoconstriction caused by neuro-humoral 
mechanisms [18], and arterial stiffness [19] on the other. These mechanisms 
lead to vascular and cardiac dysfunction and may be important in the observation 
of the “U-shaped” mortality curve reported in observational studies of pre-
dialysis blood pressure measurements in dialysis patients [20,21]. 
 Although the concept of pre-dialysis hypertension being associated with 
greater patent survival compared to those who are normotensive appears 
somewhat counterintuitive, one possibility is that patients with normal 
cardiovascular function respond to the inter-dialytic sodium gains and volume 
expansion by increasing blood pressure, whereas those with cardiac failure are 
unable to respond appropriately, and as such these patients have a higher risk of 
early mortality [22]. This would n keeping with the  previous UK National 
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Institute for Clinical Excellence (NICE) CKD 1-4 guidance [3] which suggested 
that low blood pressures (<120/60) are associated with adverse outcomes. 
Intra-dialytic hypotension remains the commonest complication of haemodialysis 
treatments [23], and the heart depends on the diastolic pressure for its own 
perfusion, and as such many studies have reported myocardial stunning occurring 
during dialysis in patients with known cardiovascular disease [24]. As such 
several studies have reported that mortality is increased for patients with 
intra-dialytic hypotension [25,26], and also for those with greatest variability in 
blood pressure, ie pre-dialysis hypertension coupled with intra-dialytic 
hypotension [27]. 
 
Blood pressure measurement in haemodialysis patients 
 It is well recognised in the general population that blood pressure varies, 
and that equipment used to measure blood pressure should be regularly 
calibrated to ensure accuracy [6], and similarly blood pressure measurements 
have been shown to differ from when patients first arrive at the dialysis centre 
to starting dialysis [8]. Coupled with dialysis centre practices, of whether anti-
hypertensive medications are taken or omitted prior to dialysis, or the 
prescription of anti-hypertensive medications which are cleared during dialysis 
mean that the convenient, but often poorly standardised, practice of measuring 
blood pressure just before and just after dialysis sessions may be profoundly 
misleading of the inter-dialytic blood pressure [8,28]. Clinical guidelines for 
recording blood pressure recommend that blood pressure should ideally be 
measured after five minutes rest in a chair, after at least 30 minutes of 
abstention from drugs which may affect blood pressure, including caffeine, 
theophylline (coffee and tea) or nicotine, with the patient seated comfortably, 
and with the arm supported at heart level, and a minimum of two measurements 
taken, several minutes apart, to allow for the alerting response to blood 
pressure measurement [29]. If the second measurement is significantly lower 
than the first, a third measurement should then be taken, with further repeats 
if there is a further fall in measured blood pressure. The mean of these later 
measurements should then be taken as the result [29]. Not surprisingly, blood 
pressure measured as recommended above is somewhat lower than that taken 
during routine clinical practice [30]. Thus, home or ambulatory blood pressure 
recordings have been recommended to confirm or refute unexpected high or low 
blood pressure readings [29], and ambulatory blood pressure studies in 
haemodialysis patients have reported that ambulatory blood pressure readings 
more closely mirror left ventricular hypertrophy than routine pre and post-
dialysis recordings [28]. 
 
Blood pressure targets for haemodialysis patients 
 
There are observational reports that pre-dialysis systolic blood pressures of 
>150-160 mmHg in haemodialysis patients are associated with increased 
mortality risk [31,32], and  that mortality is lowest with home systolic blood 
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pressure recordings between 120-130 mmHg and ambulatory systolic blood 
pressures in the range of 110-120 mmHg [33]. Ambulatory blood pressure 
recordings show that blood pressure tends to increase during the inter-dialytic 
period, particularly prior to the next dialysis session and with the longer inter-
dialytic interval with increased weight gain, so timing of the ambulatory blood 
pressure recordings in relationship to the inter-dialytic period will influence 
outcomes [34,35]. Indeed some investigators advocate 44 hour monitoring 
rather than 24 hour monitoring, however many patients find these 
measurements intrusive, and analysis of recordings may show many periods of 
absent recordings, suggesting either technical problems with recording 
measurements, or that patients have temporarily removed the device. 
 
Unfortunately there are no adequately powered prospective randomised 
controlled trials to compare one blood pressure target with another in 
haemodialysis patients. There have been a limited number of interventional 
controlled trials using particular individual antihypertensive medications, without 
necessarily achieving pre-specified blood pressure targets, some reporting 
improved outcomes[36,37], whereas one trial with blood pressure targets 
reported no specific benefit for an angiotensin receptor blocker [38]. Meta-
analysis of trials of antihypertensive medications in haemodialysis patients 
reported similar reductions in blood pressure compared to progressive 
ultrafiltration and resetting of post-dialysis target weight [39,40]. 
However, interventional studies designed to reduce post-dialysis weight in a step 
wise fashion have reported increased intradialytic hypotension [40], and 
concerns have been raised that lowering blood pressure may also increase the 
risk of intradialytic hypotension [13], which is an independent predictor of 
mortality [25-27]. Although patients with lower pre-dialysis blood pressure are 
at increased risk of mortality [20,21], observational studies have reported a 
beneficial effect on survival for the prescription of beta blockers and 
angiotensin converting enzyme inhibitors in haemodialysis patients [41]. However 
it needs to be recognised that these observational trials have a number of 
potential confounders, and results report an association and do not necessarily 
prove benefit.  
 
Summary 
There remains considerable debate both about how and when to measure blood 
pressure and the whether there should be blood pressure targets for 
haemodialysis patients. Although ambulatory blood pressure recordings are 
considered the gold standard, prolonged inter-dialytic recordings are generally 
disliked by patients, and many records have missing data points reducing 
reliability. Home blood pressure readings offer an alternative, but these can be 
falsified, or not taken in the recommended manner, and many home blood 
pressure machines are not as frequently serviced and recalibrated as hospital 
equipment (table 2). Thus for practical purposes pre and post haemodialysis 
blood pressure recordings remain the mainstay in clinical practice. However 
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there is room for improvement by introducing standardised operating 
procedures as to how and when to take blood pressure, and the number of 
measurements to be made. In some dialysis centres practices have become lax; 
taking measurements with the cuff placed over outer clothing, failing to use the 
appropriate cuff size, and failure to recalibrate blood pressure modules 
integrated into the modern day haemodialysis machine.  
 
As to actual blood pressure targets, these can only be answered by adequately 
powered prospective randomised controlled trials comparing different targets. 
Although there is currently not enough data to suggest absolute blood pressure 
targets, mounting evidence from observational studies that haemodialysis 
patients would benefit from having a systolic blood pressure < 160 mmHg, and 
for those with greater underlying vascular disease, then lower pre-dialysis 
systolic blood pressures of 140 mmHg or less may provide greater benefit. As 
such the benefits of lowering blood pressure should be considered on an 
individual cardiovascular risk basis, and future trials should stratify patients 
according to vascular morbidity and have different targets for different 
cohorts. On the other hand actively lowering systolic blood pressure to below 
130 mmHg does not appear to add benefit, and may potentially increase risk.  
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Table 1. UK National Institute for Clinical Excellence (NICE) clinical guidelines 
for blood pressure control in patients with chronic kidney disease (CKD) stages 
1-4. Proteinuria defined as an albumin/creatinine ratio of >70 mg/mmol, or a 
protein creatinine ratio > 100 mg/mmol [3]. 
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Chronic kidney disease Upper target Target range 
Systolic blood pressure mmHg  140  129 - 139 
Diastolic blood pressure mmHg < 90  
CKD and diabetes or proteinuria   
Systolic blood pressure mmHg 130 120 - 129 
Diastolic blood pressure mmHg < 80  
 
 
 
 
 
 
 
 
 
Table 2.  Quality improvement program to increase reliability of pre and post 
blood pressure recordings in haemodialysis patients. 
 
  
Reliability of equipment maintenance 
 recalibration 
Technical use of equipment chose correct blood cuff size 
 correct placement of arm cuff 
 correct positioning of arm 
 blood pressure monitor at level of heart 
Measurement patient rested in sitting or lying posture 
 repeat measurement 
 repeated measurement if 2 not similar to 1 
 report averaged measurement 
 
 
 
 
